| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0395 | A-943931 Maleate | Potent and selective histamine H4 receptor antagonist |
|
| DCC0396 | A-971432 | Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist |
|
| DCC0397 | A-987306 | Potent and selective histamine H4 receptor antagonist |
|
| DCC0398 | A-993610 | Selective TRPV1 antagonist |
|
| DCC0399 | Aa-289 | Novel potent MDM2 degrader |
|
| DCC0400 | Aa29504 | Novel potent agonist and positive allosteric modulator (Ago-PAM) of δ-GABAARs |
|
| DCC0401 | aa74-1 | Ultrapotent in vivo-active serine hydrolase inhibitor |
|
| DCC0402 | Aaa-in-b | Novel selective Inhibitor for AAA (ATPase associated with diverse cellular activities) Proteins |
|
| DCC0403 | Aak1-in-21b | Novel inhibitor of adaptor associated kinase 1 (AAK1), demonstrating improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus |
|
| DCC0404 | Aapk-25 | Novel selective dual inhibitor of Aurora/PLK, significantly inhibiting the development of the colon cancer growth and prolonging the median survival time |
|
| DCC0405 | Aaq Chloride | Photoswitchable Kv channel blocker |
|
| DCC0406 | Ab42-in-c2 | Novel inhibitor of the in vivo aggregation of Aβ1-42 |
|
| DCC0407 | Abaperidone Hydrochloride | Atypical antipsychotic, potently binging to D2 receptors and 5-HT2 receptors |
|
| DCC0408 | Aba-s2-drv8 | Novel Trojan Horse Prodrug for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity |
|
| DCC0409 | Aba-s2-nfv1 | Novel Trojan Horse Prodrug for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity |
|
| DCC0410 | Aba-x-by630 | Potent fluorescent agonist of the human A1 or A3 adenosine receptors, (dissociation constants: A1 and A3 receptors were approximately 50 and 10 nM, respectively) |
|
| DCC0411 | Abb13a | Novel GHS-R1a biased ligand, acting as a Gαq/11 inverse agonist |
|
| DCC0412 | abbott8 | Novel ligand of the dimerization interface of survivin monomers |
|
| DCC0413 | Abea-g-(d)-ala-(d)-ala-x-by630 | Novel fluorescent highly potent agonist at the adenosine A3 receptor in both reporter gene (pEC50 = 8.48 ± 0.09) and internalization assays (pEC50 = 7.47 ± 0.11) |
|
| DCC0414 | Abea-x-by630 | Novel fluorescent A3 adenosine receptor (A3‐AR) agonist |
|
| DCC0415 | Abi-231-10bb | ABI-231 analogue, disrupting tubulin polymerization, promoting microtubule fragmentation, inhibiting cancer cell migration, overcoming paclitaxel resistance in a taxane-resistant PC-3/TxR model |
|
| DCC0416 | Abi-274 | Novel potent colchicine binding site inhibitor (CBSI) and tubulin inhibitor |
|
| DCC0417 | Abl/kit-155 | Novel potent type II ABL/c-KIT dual kinase inhibitor |
|
| DCC0418 | Abl303 | Novel potent and selective inhibitor of ABHD10 (IC50 value ~ 30 nM) |
|
| DCC0419 | Abltide | Peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus |
|
| DCC0420 | Abnm-13 | Inhibitor of ribonucleotide reductase (RNR) |
|
| DCC0421 | Abp-25 | Novel cyanine-5 containing probe for cathepsin K, showing selective visualization in complex proteomes, and live cell imaging of a human osteosarcoma cell line |
|
| DCC0422 | Abrectorin | Natural TMPRSS2 inhibitor |
|
| DCC0423 | Abrusoside A | Natural hACE2 inhibitor with strong affinity for the exopeptidase site of hACE2 |
|
| DCC0424 | Abt-239 Tartrate | Potent and selective histamine H3 receptor antagonist |
|
